Frequency analysis of HLA-B7-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes in patients with multiple sclerosis and healthy controls
Journal of Neuroimmunology, ISSN: 0165-5728, Vol: 180, Issue: 1, Page: 185-192
2006
- 40Citations
- 36Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations40
- Citation Indexes40
- 40
- CrossRef32
- Captures36
- Readers36
- 36
Article Description
The Epstein-Barr virus (EBV) has been implicated in the pathogenesis of multiple sclerosis (MS), however, the mechanisms by which EBV may be involved in MS are unknown. We here have investigated the frequency of EBV-specific cytotoxic T lymphocytes (CTL) in human leukocyte antigen (HLA)-B7 + patients with MS and healthy controls using enzyme-linked immunospot assays and seven previously characterized HLA-B7-restricted immunogenic EBV peptides. Overall, there were no significant differences in the frequency of EBV-specific CTL between both groups. These data do not support the hypothesis that EBV could play a role in MS by inducing quantitatively altered EBV-specific CTL responses. Other pathogenic mechanisms for EBV in MS remain to be elucidated.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S016557280600333X; http://dx.doi.org/10.1016/j.jneuroim.2006.08.008; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33750605408&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/17023054; https://linkinghub.elsevier.com/retrieve/pii/S016557280600333X; http://www.jni-journal.com/article/S0165-5728(06)00333-X/abstract; https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=http%3A%2F%2Fwww.jni-journal.com%2Farticle%2FS0165-5728%2806%2900333-X%2Fabstract&rc=0&code=jni-site; http://acw.elsevier.com/SSOCore?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.jni-journal.com%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253DaaazMw3JrysUv4cMlaJxv%2526MAID%253DuP4ay%25252BMD89mF5FNHzKmvTQ%25253D%25253D%2526SERVER%253DWZ6myaEXBLEIcey8uceZQQ%25253D%25253D%2526ORIGIN%253D223695105%2526RD%253DRD; http://acw.elsevier.com/SSOCore/?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.jni-journal.com%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253DaaazMw3JrysUv4cMlaJxv%2526MAID%253DuP4ay%25252BMD89mF5FNHzKmvTQ%25253D%25253D%2526SERVER%253DWZ6myaEXBLEIcey8uceZQQ%25253D%25253D%2526ORIGIN%253D223695105%2526RD%253DRD; https://secure.jbs.elsevierhealth.com/action/consumeSsoCookie?redirectUri=http%3A%2F%2Fwww.jni-journal.com%2Faction%2FconsumeSharedSessionAction%3FJSESSIONID%3DaaazMw3JrysUv4cMlaJxv%26MAID%3DuP4ay%252BMD89mF5FNHzKmvTQ%253D%253D%26SERVER%3DWZ6myaEXBLEIcey8uceZQQ%253D%253D%26ORIGIN%3D223695105%26RD%3DRD&acw=&utt=; http://linkinghub.elsevier.com/retrieve/pii/S016557280600333X; http://acw.elsevier.com/SSOCore?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.jni-journal.com%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaa9FIZCGMx4Cbj48eVxv%2526MAID%253D2C6fYjDQ5cCf1CS8qJCu8Q%25253D%25253D%2526SERVER%253DWZ6myaEXBLGvmNGtLlDx7g%25253D%25253D%2526ORIGIN%253D699143653%2526RD%253DRD; http://acw.elsevier.com/SSOCore/?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.jni-journal.com%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaa9FIZCGMx4Cbj48eVxv%2526MAID%253D2C6fYjDQ5cCf1CS8qJCu8Q%25253D%25253D%2526SERVER%253DWZ6myaEXBLGvmNGtLlDx7g%25253D%25253D%2526ORIGIN%253D699143653%2526RD%253DRD; https://secure.jbs.elsevierhealth.com/action/consumeSsoCookie?redirectUri=http%3A%2F%2Fwww.jni-journal.com%2Faction%2FconsumeSharedSessionAction%3FJSESSIONID%3Daaa9FIZCGMx4Cbj48eVxv%26MAID%3D2C6fYjDQ5cCf1CS8qJCu8Q%253D%253D%26SERVER%3DWZ6myaEXBLGvmNGtLlDx7g%253D%253D%26ORIGIN%3D699143653%26RD%3DRD&acw=&utt=
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know